Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

NCT07423572 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Refractory Idiopathic Membranous Nephropathy

Interventions

DRUG: CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

Sponsor

The First Affiliated Hospital of Zhejiang Chinese Medical University